Analysis – Page 280 – Goldea Capital

Family Office of America, Inc. Reports Profitable First Quarter 2026 Financial Results

Written by Customer Service on May 18, 2026. Posted in Earnings Releases And Operating Results.

“FOFA reports positive adjusted EBITDA of $360,000, a significant accomplishment for such a young and fast-growing company.” CENTENNIAL, Colo., May 18, 2026 (GLOBE NEWSWIRE) — OTCMarkets: FOFA OTC Markets: FOFA OTCMarkets: FOFA — Family Office of America, Inc. (“FOFA,” “Family Office of America,” or the “Company”) today announced financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsNet revenue totaled $783,126 for the three months ended March 31, 2026, compared to no revenue in the prior year period. Gross profit totaled $783,126. Income from operations was $274,872, compared to an operating loss of $(103,321) in the prior year period. Net income totaled $263,789, or $0.01 basic and diluted earnings per share, compared to a net loss of $(103,321), or...

C3is Inc. reports robust financial and operating results for the first quarter of 2026, with a 358% increase in Adjusted Net Income

Written by Customer Service on May 18, 2026. Posted in Earnings Releases And Operating Results.

ATHENS, Greece, May 18, 2026 (GLOBE NEWSWIRE) — C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing tanker and dry bulk seaborne transportation services, announced today its unaudited financial and operating results for the first quarter ended March 31, 2026. OPERATIONAL AND FINANCIAL HIGHLIGHTSOur handysize dry bulk carriers are employed on time charters of short-term durations, producing steady cash flows, while our Aframax tanker operates in the spot market, currently achieving voyage charter rates of around $115,000 per day. The Company has also entered into agreements to acquire two product tankers for an aggregate consideration of $39.8 million. One of these tankers was delivered in April 2026, while the second is expected to be delivered in the third quarter of 2026. These acquisitions increase the...

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

Written by Customer Service on May 18, 2026. Posted in Public Companies.

GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This follows Emergent’s recent announcement that Singapore’s Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] to include prevention of mpox disease in adults determined to be at high risk for mpox infection. “We are pleased to receive this approval for ACAM2000® from SFDA for immunization against smallpox and mpox in high-risk individuals,” said Simon Lowry, chief medical...

Zeo Energy Corp. Reports First Quarter 2026 Financial Results

Written by Customer Service on May 18, 2026. Posted in Earnings Releases And Operating Results.

Revenue increases 50% over prior year quarter, driven by increase in solar system installations NEW PORT RICHEY, Fla., May 18, 2026 (GLOBE NEWSWIRE) — Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” “Zeo Energy,” or the “Company”), a provider of residential solar and commercial long-duration energy-storage solutions, today reported financial results for the first quarter March 31, 2026. First Quarter Financial and Operational HighlightsFirst quarter revenue was $13.2 million, up 50% from $8.8 million in the prior year period. Gross profit margin for the quarter increased to $5.6 million from $4.0 million in the prior year period. Contribution profit increased to $2.2 million from a loss of $(2.8) million in the prior year period. First quarter Adjusted EBITDA, a non-GAAP financial measure, was a loss of $(2.9) million, an improvement...

Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation

Written by Customer Service on May 18, 2026. Posted in Public Companies.

THE WOODLANDS, TX, May 18, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two abstracts highlighting the Company’s innovative transvascular nerve-targeting platform technology have been accepted for presentation at EuroPCR 2026, the world-leading course in interventional cardiovascular medicine, taking place May 19–22, 2026 in Paris, France. The accepted abstracts titled, “Pain mitigation in pancreatic cancer: An analysis of denervation via transvascular RF ablation” and “Illuminating the nervous system with transvascular precision-guided technology”, further recognize the growing clinical and scientific interest in Autonomix’s differentiated approach to peripheral nerve modulation...

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

Written by Customer Service on May 18, 2026. Posted in Public Companies.

New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing Halneuron® 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension study. Based on a positive interim assessment demonstrating a Halneuron® 4-week treatment effect versus placebo, Dogwood previously submitted plans to FDA to support commencement of a Halneuron®...

Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

Written by Customer Service on May 18, 2026. Posted in Public Companies.

Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the signing of a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. The agreement will fund a comprehensive preclinical study evaluating the metabolic efficacy of MEAI (CMND-100), both in combination with and as a maintenance therapy following tirzepatide treatment in diet-induced obese (“DIO”) mice. The research will be conducted by Professor Joseph (Yossi) Tam and his team at the Obesity and Metabolism Laboratory...

AITX’s RAD Launches SCANNA to Unlock Smarter Security from Existing Cameras

Written by Customer Service on May 18, 2026. Posted in Public Companies.

New Solution Accelerates an Organization’s Move to AI Intelligent Security Operations Detroit, Michigan, May 18, 2026 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCID:AITX), a global leader in AI-driven security and productivity solutions, along with its wholly owned subsidiary, Robotic Assistance Devices, Inc. (RAD), today announced SCANNA™ (Security Camera Automated Network & Node Assistant), a new software solution designed to rapidly connect existing IP security cameras and Network Video Recorder systems (NVR) into RADSoC™, the Company’s advanced security operations and incident management platform. SCANNA simplifies and accelerates the integration of existing camera infrastructure into RADSoC and SARA™ driven workflows, helping small and mid-sized organizations...

CPI Aerostructures Reports First Quarter 2026 Results

Written by Customer Service on May 18, 2026. Posted in Earnings Releases And Operating Results.

First Quarter 2026 vs. First Quarter 2025Revenue of $17.4 million compared to $15.4 million; Gross profit of $4.5 million compared to $1.6 million; Gross profit margin of 25.8% compared to 10.7% (21.6% excluding A-10 Program impact); Net income of $1.2 million compared to net (loss) of $(1.3) million; Earnings per share of $0.10 compared to (loss) per share of $(0.10); Adjusted EBITDA(1) of $2.1 million compared to $(0.8) million ($1.4 million excluding A-10 Program impact);EDGEWOOD, N.Y., May 18, 2026 (GLOBE NEWSWIRE) — CPI Aerostructures, Inc. (“CPI Aero” or the “Company”) (NYSE American: CVU) today announced financial results for the first quarter ended March 31, 2026, delivering significant year‑over‑year improvements driven by favorable product mix, operational efficiencies, and continued execution across key Aerospace...

Lendlease REIT Delivers Strong Operating Performance and Disciplined Capital Management

Written by Customer Service on May 18, 2026. Posted in Earnings Releases And Operating Results.

Key HighlightsPositive retail rental reversion of 12.2%1 achieved in 3Q FY2026. Positive rental uplift of 1.5%2 for office Building 1 and 2 in Milan, effective from April 2026. Year-to-date tenant sales up 17.6%3 YoY. On a like‑for‑like basis, excluding PLQ Mall, tenant sales also increased 2.5% YoY. Portfolio occupancy improved to 95.3%4 from 94.9%4 in the preceding quarter. Gearing stood at 38.7% as at 31 March 2026. Post quarter-end, S$120 million perpetual securities were issued at 4.28% per annum. Completed refinancing of the PLQ Mall loans, securing approximately S$2 million in annual all‑in debt cost savings, in line with acquisition underwriting5. Electricity tariffs contracted at fixed rates till FY2028, de-risking against potential rate hikes. Targeted enhancement works at PLQ Mall are underway and expected to be completed...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals